trending Market Intelligence /marketintelligence/en/news-insights/trending/rxG65_gnj4-b1Dpn7w-VFA2 content esgSubNav
In This List

GlaxoSmithKline adds 2 execs to board

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


GlaxoSmithKline adds 2 execs to board

GlaxoSmithKline PLC named CEO Designate Emma Walmsley and President of R&D Patrick Vallance to the board as executive directors, effective Jan. 1, 2017.

Stacey Cartwright will step down from the board, effective Dec. 31. She leaves after serving for almost 6 years as a nonexecutive director.

In addition, Andrew Witty and Moncef Slaoui will step down from the board March 31, 2017. Slaoui will serve as adviser to the company and the board from April 1, 2017, until his retirement June 30, 2017.